3-(2,5-dioxoimidazolidin-1-yl)benzoic acid | 939999-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,5-dioxoimidazolidin-1-yl)benzoic acid
• 英文别名: 3-(2,5-Dioxo-imidazolidin-1-yl)-benzoic acid
• CAS: 939999-27-6
• 化学式: C₁₀H₈N₂O₄
• 分子量: 220.185
• InChiKey: SSNBOSIIRMGAEV-UHFFFAOYSA-N

物化性质

• 密度：
  1.513±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2,5-dioxoimidazolidin-1-yl)benzoic acid 在 哌啶 、 氯化亚砜 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent

  摘要：

  Inhibition of DNA methyltransferase 1 (DNMT1) can reverse the malignant behavior of cancer cells by restoring expression of aberrantly silenced genes that are required for differentiation, senescence, and apoptosis. Clinically used DNMT1 inhibitors decitabine and azacitidine inhibit their target by covalent trapping after incorporation into DNA as azacytidine analogs. These nucleoside compounds are prone to rapid enzymatic inactivation in blood, posing challenges to the development of purely epigenetic dosing schedules. Non-nucleoside compounds that suppress expression or function of DNMT1 may overcome this problem. Using a high-throughput PCR-based site specific chromatin condensation assay, we identified a compound that reactivated Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) in myeloma cells and suppressed expression of DNMT1 from a library of 5120 chemically diverse small molecules. Lead optimization was performed to generate 26 new analogs with lung cancer proliferation and DNMT1 expression as activity readout. Two of the new derivatives showed 2 fold improvement of growth inhibiting potency and also decreased DNMT1 protein levels in lung cancer cells. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2016.01.020
• 作为产物：
  描述：

  在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 反应 8.0h， 生成 3-(2,5-dioxoimidazolidin-1-yl)benzoic acid
  参考文献：
  名称：

  Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors

  摘要：

  这项发明涉及式(I)的新型替代哌啶衍生物，其中R1、R2、R3、R4、R5、R6、R7和X的定义如说明书和权利要求中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。

  公开号：

  US20070129544A1

文献信息

• [EN] HYDANTOINE DERIVATIVES AS CD38 INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOÏNE COMME INHIBITEURS DE CD38
  申请人：SANOFI SA

  公开号：WO2014180544A1

  公开（公告）日：2014-11-13

  The present invention relates to compounds of formula (I) which have CD38 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of inflammatory diseases.

  本发明涉及具有CD38抑制活性的化合物(I)的公式，可作为预防和/或治疗炎症性疾病药物的有效成分。
• Hydantoine derivatives as CD38 inhibitors
  申请人：SANOFI

  公开号：EP2801573A1

  公开（公告）日：2014-11-12

  The present invention relates to compounds of formula I which have CD38 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of inflammatory diseases.

  本发明涉及具有CD38抑制活性的化合物，可作为预防和/或治疗炎症性疾病药物的有效成分。
• Heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US07645776B2

  公开（公告）日：2010-01-12

  The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  本发明涉及一种新的取代哌啶衍生物的化合物，其化学式为（I），其中R1，R2，R3，R4，R5，R6，R7和X的定义如说明书和权利要求书中所述，以及其生理上可接受的盐和酯。这些化合物可以抑制L-CPT1并可用作药物。
• HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1959951A1

  公开（公告）日：2008-08-27
• US7645776B2
  申请人：——

  公开号：US7645776B2

  公开（公告）日：2010-01-12